Analyst opines that Ironwood’s Linzess sales will hit $1.4B by 2018

A survey of doctors commissioned by Leerink Swann found that while Ironwood Pharmaceuticals’ drug to treat irritable bowel syndrome has captured a smaller percentage of the market since its launch in December, patients are staying on the drug longer...